Drug reference

lumefantrine

Arylamino alcohol · Antimalarial

Arylamino alcoholAntimalarial

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

NeurolepticsSevereTextbookKDT 7e · p816-835
AbarelixSevereDatabaseDDInter
AbirateroneSevereDatabaseDDInter
AdenosineSevereDatabaseDDInter

Mechanism

Lumefantrine is an orally active, high efficacy, long-acting erythrocytic schizontocide, chemically and mechanistically related to halofantrine and mefloquine. Additionally, it affects nucleic acid and protein synthesis of the parasite. It acts synergistically with artemether.

Indications

treatment of uncomplicated malaria (as artemether-lumefantrine)uncomplicated CQ-resistant falciparum malaria (as part of ACT)Uncomplicated falciparum malaria (only in combination with artemether as FDC tablets)

Dosing

Adult: 4 tablets. Day 1: 2 doses separated by 8 h; thereafter 1 dose twice daily 2 days
Pediatric: Weight (kg) 5–15: 1 tablet/dose; 15–25: 2 tablets/doses; 25–<35: 3 tables/doses; >35: 4 tablets/doses. Use same 3-day schedule as adults

Pharmacokinetics

Onset

intermediate

Duration

long

Half-life

4 to 5 days

Bioavailability

increased with high-fat meal

Protein binding

99%

Excretion

Metabolized predominantly by CYP3A4

Contraindications

children weighing <5 kg
pregnant women
women breastfeeding infants weighing <5 kg
First trimester of pregnancy
Breastfeeding
Patients receiving Q-Tc prolonging drugs

Side effects

Common

headache (adults)anorexia (adults)dizziness (adults)asthenia (adults)arthralgia (adults)myalgia (adults)fever (children)cough (children)vomiting (children)loss of appetite (children)headache (children)HeadacheDizzinessSleep disturbancesAbdominal painArthralgiaMyalgiaPruritusRashnauseavomitingdiarrheaanorexia

Serious

QTc prolongation

Pregnancy & lactation

Pregnancy

Lactation

not recommended for women breastfeeding infants weighing less than 5 kg

Drug interactions

Neuroleptics

Severe

Textbook

Altered metabolism and potential increased levels of drugs metabolized by CYP2D6.

Should not be given with drugs metabolized by CYP2D6.

Source: KDT 7e · p816-835

Abarelix

Severe

Database